OPPM
ACIU icon

Opus Point Partners Management’s AC Immune ACIU Stock Holding History

Opus Point Partners Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-39,801
Closed -$201K – 64
2019
Q1 		$201K Buy
+39,801
New +$253K 0.27% 73

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Opus Point Partners Management's ACIU Position: Q2 2019 in Review

Opus Point Partners Management sold out of AC Immune (ACIU) in Q2 2019, closing a stake of 39,801 shares — an estimated $201K sold.

Opus Point Partners Management first reported a position in ACIU in Q1 2019 and held it in 1 quarter. The position peaked at $201K in Q1 2019. 40 funds tracked by Wall St. Rank hold ACIU as of Q2 2019.

  • Opus Point Partners Management reported no remaining AC Immune position as of Q2 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 39,801 AC Immune shares in Q2 2019, an estimated $201K.
  • Opus Point Partners Management first reported a position in AC Immune in Q1 2019 and held it in 1 quarter.
  • Opus Point Partners Management's AC Immune position peaked at $201K in Q1 2019.
  • 40 funds tracked by Wall St. Rank held AC Immune as of Q2 2019.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.